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Abstract: Environmental factors clearly influence the pathogenesis of 
Type 1 diabetes, an autoimmune disease. We have studied gut microbiota as 
important environmental agents that could affect the initiation or 
progression of type 1 diabetes especially in the prenatal period. We used 
neomycin targeting mainly Gram negative or vancomycin, targeting mainly 
Gram positive bacteria, to treat pregnant NOD mothers and to study 
autoimmune diabetes development in their offspring. Neomycin-treated 
offspring were protected from diabetes, while vancomycin-treated 
offspring had accelerated diabetes development, and both antibiotics 
caused distinctly different shifts in gut microbiota composition compared 
with the offspring from untreated control mice. Our study demonstrated 
that neomycin treatment of pregnant mothers leads to generation of 
immune-tolerogenic antigen-presenting cells (APCs) in the offspring and 
these APCs had reduced specific autoantigen presenting function both in 
vitro and in vivo. Moreover, the protection from diabetes mediated by 
tolerogenic APCs was vertically transmissible to the second generation. 
In contrast, more diabetogenic inflammatory T cells were found in the 
lymphoid organs of the offspring from the vancomycin-treated pregnant 
mothers. This change however was not transmitted to the second 
generation. Our results suggested that prenatal exposure to antibiotic 
influenced gut bacterial composition at the earliest time point in life 
and is critical for consequent education of the immune system. As 
different bacteria can induce different immune responses, understanding 
these and how to generate self-tolerogenic APCs could be important for 
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Abstract 
Environmental factors clearly influence the pathogenesis of Type 1 diabetes, an autoimmune 
disease. We have studied gut microbiota as important environmental agents that could affect the 
initiation or progression of type 1 diabetes especially in the prenatal period. We used neomycin, 
targeting mainly Gram negative or vancomycin, targeting mainly Gram positive bacteria, to treat 
pregnant NOD mothers and to study autoimmune diabetes development in their offspring. 
Neomycin-treated offspring were protected from diabetes, while vancomycin-treated offspring had 
accelerated diabetes development, and both antibiotics caused distinctly different shifts in gut 
microbiota composition compared with the offspring from untreated control mice. Our study 
demonstrated that neomycin treatment of pregnant mothers leads to generation of 
immune-tolerogenic antigen-presenting cells (APCs) in the offspring and these APCs had reduced 
specific autoantigen-presenting function both in vitro and in vivo. Moreover, the protection from 
diabetes mediated by tolerogenic APCs was vertically transmissible to the second generation. In 
contrast, more diabetogenic inflammatory T cells were found in the lymphoid organs of the offspring 
from the vancomycin-treated pregnant mothers. This change however was not transmitted to the 
second generation. Our results suggested that prenatal exposure to antibiotic influenced gut bacterial 
composition at the earliest time point in life and is critical for consequent education of the immune 
system. As different bacteria can induce different immune responses, understanding these 
differences and how to generate self-tolerogenic APCs could be important for developing new 
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Phorbol 12-myristate 13-acetate; SI, stimulation index; SPL, spleen; MLN, mesenteric 
lyŵph Ŷodes; PLN, paŶĐreatiĐ lyŵph Ŷodes; PP, Peyer’s patches; APC, antigen presenting 
cell; DC, dendritic cell; IGRP, islet-specific glucose-6-phosphatase catalytic 
subunit-related protein; G+, Gram positive; G-, Gram negative 
 
1. Introduction 
Type 1 diabetes (T1D) is a T cell-mediated autoimmune disease which commonly 
presents in childeren and young adults [1]. The insulin-producing beta cells of the 
pancreatic islets are damaged and destroyed by activated autoreactive T cells resulting in 
the poor regulation of blood sugar and hyperglycemia [2]. Many genes determine 
susceptibility to the disease although the most important genetic susceptibility gene 
region, IDDM1 is encoded within the HLA [3-5]. However, a sharp rise in T1D incidence 
has been seen in recent years in genetically susceptible young children and individuals 
who do not carry high risk HLA alleles [6] and this has also taken place over a relatively 
short period of time. This strongly suggests that non-genetic factors, especially 
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environmental factors influence disease development. 
The gut microbiota maintain homeostasis of gut epithelia and permeability and the 
interaction between gut epithelia and the bacteria promotes the development of a 
normal immune system [7]. Altered composition of gut microbiota has been found to be 
associated with the development of various diseases including obesity and type 2 
diabetes [8], metabolic and liver disease [9], intestinal inflammatory syndrome [10], 
allergic disorders [11], Alzheimer’s disease [12] and autoimmune diseases [13-15]. 
Increasing evidence suggests that changes in commensal microbiota correlate with 
the development of T1D in both mouse models and humans [16, 17]. We and others 
have demonstrated that T1D development is modulated by gut microbiota [18-21]. A 
recent longititudinal childhood study suggested a change of the composition of gut 
microbiota prior to the clinical onset of T1D in the children who were at high risk of 
developing T1D [22]. 
 Early life exposure to the gut microbiota is critical for the maturation of the host 
immune system as well as maintaining health later on in life [23] and colonization with 
specific gut microbiota is strongly influenced by microbial exposures at birth [24]. Thus, 
the mode of infant delivery and the methods of feeding have profound impact on the 
composition of gut microbiota of the infants, which in turn affects health later in life [25, 
26]. Millions of people have been saved from life-threatening infections since the 
discovery of antibiotics; however, recent studies have shown that exposure to antibiotics 
early in life can have undesirable consequences including the development of obesity 
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and asthma [27-29]. Using a short exposure to a combination of Neomycin/Polymyxin 
B/Streptomycin, reducing Gram negative (G-) gut bacteria in the non-obese diabetic 
(NOD) mouse model of human T1D, we demonstrated that the mice were significantly 
protected from T1D development [20]. This protection was most striking when mice 
were treated in the prenatal period [20]. Thus, the time of life at which antibiotics are 
administered is crucial in studying the effect of gut microbiota on T1D development. In 
addition to the time of antibiotic exposure, we hypothesized that the type of antibiotic is 
also important. To test our hypothesis we investigated the effect of early exposure to 
two antibiotics, vancomycin and neomycin, that have very different functional features, 
on T1D development and studied the underlying mechanism. 
 
2. Materials and Methods 
2.1 Mice 
Female NOD/Caj mice were originally obtained from the Jackson Laboratory and 
have been maintained at Yale University for many years. BDC2.5NOD and NY8.3NOD T 
cell receptor (TCR) transgenic mice were purchased from the Jackson Laboratory. The 
mice used in this study were kept in specific pathogen–free conditions with a 12-hour 
dark/light cycle, in individually-ventilated filter cages with autoclaved food, at the Yale 
University animal facility. The use of the animals in this study was approved by the Yale 
University Institutional Animal Care and Use Committee. 
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2.2 Antibiotic treatment 
We treated pregnant (plugged) NOD mice with neomycin or vancomycin (all from 
Sigma) via drinking water at a final concentration of 1mg/ml for neomycin, 0.5mg/ml for 
vancomycin. The treatment was withdrawn within 24 hours after birth and diabetes 
development was observed in the offspring. The offspring from neomycin- or 
vancomycin-treated mothers were designated as Neo- or Van-mice. 
 
2.3 Gut permeability assay 
Gut permeability assay was performed as previously described [30]. Briefly, the mice 
were gavaged with FITC-dextran (600mg/kg) (Sigma) after fasting overnight. Blood 
samples were collected at 4 hours after gavage. After serial dilution, the serum samples 
were plated in a 96-well plate and read on a fluorescence spectrophotometer. Serum 
samples from non-FITC-dextran treated NOD mice were used as baseline and different 
concentrations of FITC-dextran were used to generate the standard curve. The test 
results were calculated based on the standard curve and baseline levels. 
 
2.4 Intracellular cytokine (ICC) staining 
For ICC staining, 10
6
 cells were cultured for 4 hours with 50ng/ml PMA (Sigma), 
5ϬϬŶg/ŵl of ioŶoŵyĐiŶ ;“igŵaͿ aŶd ϭμl/ŵl of Golgiplug ;BD BiosĐieŶĐeͿ, ďefore staiŶiŶg 
with mononoclonal antibodies (mAbs) against surface markers. After fixation, cells were 
stained with different intracellular anti-cytokine mAbs (Biolegend) and their expression 
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was analyzed by flow cytometry. 
 
2.5 Real time quantitative PCR (qPCR) 
SFB-specific forward (SFB-F 5’-AGGAGGAGTCTGCGGCACATTAGC-3’Ϳ aŶd reǀerse 
primers (SFB-R 5’-TCCCCACTGCTGCCTCCCGTAG-3’Ϳ were used to determine the relative 
abundance of SFB in the total bacterial DNA. Total 16S rRNA was used as the control and 
the results were analyzed by the delta-delta CT method after normalization with 16S 
rRNA. Each sample was analyzed in triplicate and the experiments were repeated twice. 
 
2.6 16S rRNA sequencing analysis 
Fecal samples were collected from both pregnant mothers and their offspring and 
DNA extraction was performed as previously described [28]. The V4 region of the 
bacterial 16S ribosomal gene was amplified from each DNA sample using a barcoded, 
broadly conserved, ďaĐterial forǁard priŵer ;5’-GTGCCAGCMGCCGCGGTAA-3’Ϳ aŶd 
reǀerse priŵer ;5’-GGACTACHVGGGTWTCTAAT-3’Ϳ. The PCR products were purified with 
a Qiagen gel extraction kit. After quantification of DNA concentration using the Qubit 
dsDNA HS assay kit, equimolar amounts of each sample were pooled and used for 
pyrosequencing. Sequencing was performed on the Ion Torrent Personal Genome 
Machine (PGM) sequencing system (Life Technologies) using 200 bp read chemistry. The 
sequencing data were analyzed with QIIME software package (http://qiime.org) and 
UPARSE pipeline to pick operational taxonomic units (OTUs). Taxonomy assignment was 
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performed at various levels using representative sequences of each OTU. G+/G- ratio was 
calculated using the most abundant Gram positive (G+) Firmicutes plus Actinobacteria 
contents divided by the most abundant Gram negative (G-) Bacteroidetes plus 
Proteobacteria contents. 
 
2.7 Cell purification 
Total APCs were purified by removing CD4
+
 (clone GK1.5) and CD8
+
 T cells (clone 
T1B105) using mAb hybridoma supernatants, followed by magnetic bead (conjugated 
with goat anti-Rat IgG) separation. T cells were purified by removing MHC class II
+
 cells 
(clone 10.2.16) and B cells (anti-mouse IgM and IgG (Qiagen)) using mAb hybridoma 
supernatants and magnetic bead separation. The purity of the Đells ǁas routiŶely ≥9Ϭ%, 
analyzed by flow cytometry. 
 
2.8 T cell proliferation assay 
Purified CD4
+
 BDC2.5 or CD8
+
 NY8.3 T cells (10
5
/well) were co-cultured with 
irradiated APCs (5 × 10
4
/well) from experimental mice, in triplicate, in the presence or 
absence of specific antigens (Ag) - BDC2.5 mimotope peptide (RTRPLWVRME) or 
IGRP206-214 peptide (VYLKTNVFL), respectively. Cell proliferation was determined by 
stimulation index (SI), which was calculated by [
3
H]-thymidine incorporation (cpm) with 
Ag/[
3
H]-thymidine incorporation (cpm) without Ag. 
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2.9 Lymphocyte Adoptive Transfer 
Total splenocytes or purified T cells from diabetic NOD mice were injected into 
irradiated recipient mice (10
7
/mouse, i.v.). The recipient mice were monitored for 
diabetes every week. Purified T cells from diabetic NOD mice (3x10
6
/mouse) with or 
without total APCs from neomycin-treated or untreated NOD mice (3x10
6
/mouse) were 




Statistical analysis was performed using GraphPad Prism software. P values of < 0.05 
were considered significant. 
 
3. Results 
3.1 Prenatal neomycin or vancomycin treatment has different impacts on diabetes 
development in NOD mice. 
To investigate the effect of single antibiotic treatment, targeting different bacterial 
species, on diabetes development, we treated two NOD mating groups (n=4-6 breeding 
pairs/group) with neomycin or vancomycin, individually, in the drinking water after the 
females were plugged (+/- 24 hours). As controls, we included a group of NOD mice 
without treatment. The antibiotics were withdrawn immediately after delivery of the 
pups and diabetes development of the offspring was monitored on a weekly basis. In 
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sharp contrast to diabetes incidence in the progeny from neomycin-treated breeders, 
vancomycin treatment strongly accelerated T1D development and 100% of mice were 
diabetic by the age of 21 weeks old (Fig.1), while prenatal neomycin treatment 
significantly protected NOD mice from diabetes development (Fig.1). Our results indicate 
that exposure to different antibiotics early in life can affect T1D development very 
differently. 
 
3.2 Prenatal antibiotic treatment altered the cecum weight and gut permeability of the 
progeny 
To investigate whether prenatal antibiotic treatment affected the cecal mass, where 
a large number of gut bacteria reside, we measured the cecal weight and found a 
significant increase of cecal mass and the ratio of cecal weight to body weight in the 
progeny of antibiotic-treated breeders compared to the progeny from untreated 
breeders (Fig.2A). The enlargement of the cecum was greater when the progeny were 
younger (4-5 weeks old, Fig.2A) and the increased cecal mass was less striking at 16 
weeks of age (data not shown). It is interesting that the increased cecal mass was 
independent of the type of antibiotic used (Fig.2A). 
Next, we examined the effect of prenatal antibiotic exposure on gut permeability. It 
is interesting that prenatal exposure of neomycin reduced gut permeability whereas 
prenatal exposure to vancomycin increased gut permeability compared to the mice 
without prenatal antibiotic exposure (Fig.2B). This suggests that prenatal exposure of 
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vancomycin leads to a ͞leaky͟ gut. 
 
3.3 Prenatal antibiotic treatment reduced the cellularity of gut associated lymphoid 
tissue (GALT) of the progeny 
To test if prenatal antibiotic exposure affected the development of GALT, we 
examined mesenteric lymph nodes (MLN) and Peyer’s patĐhes (PP) of the progeny that 
were exposed to neomycin or vancomycin. As expected, the cellularity of MLN and PP 
from prenatally antibiotic-exposed mice was significantly reduced compared to the 
progeny without antibiotic exposure (Fig.2C); however, the reduction was more marked 
in the mice that were prenatally exposed to vancomycin compared with the 
neomycin-exposed progeny (Fig.2C). We did not find an obvious difference in the 
composition of T or B lymphocytes (data not shown). Our results also suggest that 
diabetes protection or acceleration associated with prenatal antibiotic exposure is most 
likely mediated by the change in gut bacteria, which affects the immune system. 
 
3.4 Prenatal antibiotic treatment altered the composition of gut microbiota in the 
breeding mothers and their progeny 
To examine the composition of gut microbiota, we performed 16S rRNA sequencing. 
We first studied the breeding mothers before and after administration of antibiotic water. 
There were no obvious differences between any of the breeding mothers before 
antibiotic administration (data not shown). However, after the 3-week antibiotic 
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treatment, we have observed a clear change in these females. At the phylum level, 
Actinobacteria, Bacteroidetes, Cyanobacteria from antibiotic-treated breeding females 
were significantly different from non-treated breeding female mice (Fig.3A). It is 
interesting that more Bacteroidetes were found in neomycin-treated mice and more 
Firmicutes were found in vancomycin-treated mice (Fig.3A). Actinobacteria were 
significantly reduced in both neomycin- and vancomycin-treated breeding mothers 
compared to untreated mothers (Fig.3B); however, we found an increase in 
Cyanobacteria in neomycin-treated breeding mothers compared to either vancomycin- 
treated mothers or untreated controls (Fig.3B). We found more alterations in gut 
microbial taxa at the genus level (Fig. 3C) as well as other levels (data not shown) in 
treated mice compared with controls. 
We further examined the alteration of gut microbiota by 16S rRNA sequencing to 
identify which specific bacterial taxa were changed after prenatal antibiotic exposure. 
We found that the composition of gut bacteria in these mice was significantly altered, 
even though the mice were not directly exposed to the antibiotics. The mothers treated 
with vancomycin and neomycin had significantly reduced Actinobacteria compared to 
the control mice. Similar to their mothers, the mice prenatally exposed to vancomycin 
showed significantly reduced Actinobacteria, but an increase in Proteobacteria 
compared to the control mice or those treated with neomycin at 4 weeks of age (Fig.3D). 
However, unlike their mothers, neither Actinobacteria (Fig.3D), nor Cyanobacteria (data 
not shown) were altered in the mice prenatally exposed to neomycin. As the 
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composition of the gut microbiota changes with age, we also investigated the gut 
microbiota in the progeny at 15 weeks. It is interesting that the differences in the 
abundance of Proteobacteria seen in the mice prenatally exposed to vancomycin 
remained high even at 15 weeks old (Fig.3D), while Actinobacteria remained low (Fig.3D). 
In contrast, the abundance of Actinobacteria in the mice prenatally exposed to neomycin 
was elevated with age (Fig.3D). We also examined the overall G+/G- ratio in both Neo- 
and Van-treated mice. Although the Van group did not show differences compared with 
the untreated NOD group, a significant reduction was presented in the Neo group (Fig. 
3E). 
Segmented filamentous bacteria (SFB) have been reported to be associated with 
T1D protection in NOD mice [31]. To test whether SFB play a role in diabetes protection 
in the mice prenatally exposed to neomycin, we examined the abundance of SFB in the 
fecal samples from these mice by qPCR with SFB-specific primers. As controls, we 
included the fecal samples from the mice prenatally exposed to vancomycin, which 
accelerated diabetes development and the samples from the untreated progeny. We 
found that SFB were depleted in both groups of mice prenatally exposed to antibiotics, 
either neomycin or vancomycin (Fig.3F). Our results suggest that SFB do not play a role in 
diabetes protection in the mice prenatally exposed to neomycin. 
 
3.5 The effect of antibiotics on T cell phenotype 
Since T1D is a T cell-mediated disease, we investigated the impact of prenatal 
 14 
exposure to antibiotics on T cell phenotype. We examined T cells from spleen (SPL), 
mesenteric lymph node (MLN), pancreatic lyŵph Ŷodes ;PLNͿ aŶd Peyer’s patĐhes ;PPͿ of 
the mice from the three groups. The mice prenatally exposed to vancomycin showed a 
significant decrease in naïve T cell markers (CD44-CD62L+) and a highly increased 
number of CD4+ T cells expressing memory/effector markers in most of the lymphoid 
tissues examined (Fig.4A). This was even more marked in PP, the gut associated 
lymphoid tissue (GALT). The same profile was also found for CD8+ T cells (data not 
shown). In line with this phenotype, CD4+ T cells from the mice prenatally exposed to 
vancomycin also expressed significantly more inflammatory cytokine IL-17 (Fig.4B) and 
CD8+ T cells expressed significantly more IFN- and TNF- in the four lymphoid tissues 
examined (Fig.4C, D). Our results indicated that accelerated diabetes in the mice 
prenatally exposed to vancomycin was mediated by the alteration of gut microbiota 
which enhanced inflammatory T cells. In contrast, it is interesting that neomycin 
treatment did not have an obvious impact on these inflammatory T cells compared to 
the control mice. We did not observe enhanced anti-inflammatory T cells including 
FoxP3+ Tregs and IL-10-producing T cells in diabetes-protected mice that were prenatally 
exposed to neomycin (data not shown). 
 
3.6 The effect of prenatal antibiotic exposure on the phenotype of antigen presenting 
cells (APCs) 
To investigate whether prenatal antibiotic exposure affects the phenotype and 
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function of the APCs, we first examined the phenotype of the APCs in spleen (non-GALT) 
and MLN (GALT) from the progeny of the three groups. Whereas vancomycin clearly 
altered the T cell phenotype, neomycin appears to have stronger impact on the APCs 
(Fig.5A, B). The expression of the co-stimulatory molecules, CD80 and CD86, on CD11b+ 
(pan macrophage marker) and CD11c+ (pan dendritic cell, (DC) marker) cells were 
significantly down-regulated in both spleen and MLN from mice prenatally exposed to 
neomycin. Furthermore, we examined the phenotype of the APCs in response to Toll-like 
receptor (TLR) agonist stimulation including LPS (TLR4) and CpG (TLR9), both of which 
are enriched in bacteria. IFN- expression was significantly lower in macrophages and 
DCs from mice prenatally treated with neomycin, but not in APCs from mice prenatally 
treated with vancomycin (Fig. 5C). Similar to the phenotype found in the in 
vitro-stimulated APCs, significantly fewer IFN--expressing macrophages and DCs were 
found in the mice prenatally exposed to neomycin, when studied immediately ex-vivo 
(Fig.5D). 
 
3.7 The function of APCs from mice born to mothers treated with antibiotics in gestation. 
We tested the antigen-presenting function of total APCs from the mice prenatally 
exposed to neomycin and vancomycin using BDC2.5 CD4+ and NY8.3 CD8+ T cell 
proliferation as readouts. Here, the proliferative responses of the antigen-specific T cells 
reflect the antigen-presenting ability of the APCs to the T cells. Our results showed that 
APCs from the mice prenatally exposed to neomycin had a weaker ability to stimulate 
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both BDC2.5 CD4+ (Fig.6A) and NY8.3 CD8+ (Fig.6.B) T cells compared to the APCs from 
the control mice or the APC from the mice prenatally exposed to vancomycin (Fig.6). It is 
interesting that APC from prenatally vancomycin-treated mice appear to stimulate 
BDC2.5 CD4+ T cells most strongly, correlated with accelerated diabetes development in 
the vancomycin-treated mice. 
 
3.8 Diabetes protection is transferable 
Our results indicated the protection from diabetes in the offspring of 
neomycin-treated mice was correlated with APC less able to stimulate pathogenic cells. 
We therefore tested whether the diabetes phenotype generated by prenatal exposure to 
antibiotics could be transferred by T cells or APCs. To test our hypothesis, we performed 
three sets of adoptive transfer experiments. In the first set, we used the mice prenatally 
exposed to antibiotics or controls as the recipients. These mice were irradiated so that 
their endogenous T cell proliferative function was impaired but not the ability of the 
APCs to present antigens. Total splenocytes from unmanipulated diabetic NOD mice 
were transferred to the irradiated recipients. As shown in Fig.7A, the recipients that 
were prenatally exposed to neomycin had significantly delayed diabetes onset compared 
to control non-antibiotic-treated or vancomycin-exposed mice, although all the mice in 
the study ultimately developed diabetes at a later time. In the second set of adoptive 
transfer experiments, we transferred purified splenic T cells from unmanipulated 
diabetic NOD mice to the irradiated mice that were prenatally exposed to antibiotics or 
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control non-antibiotic-treated mice. When the APCs were depleted from transferred 
splenocytes, diabetes development in the recipients that were prenatally exposed to 
neomycin was also delayed compared to non-antibiotic treated NOD control group 
(Fig.7B), but the effect was less strong compared to transferring total splenocytes (Fig.7A) 
and the difference with prenatally vancomycin-exposed mice was diminished. Lastly, we 
tested the APC function directly. We used irradiated NOD mice as the recipients and 
purified splenic APCs from the mice prenatally exposed to neomycin or controls as donor 
cells together with purified T cells from unmanipulated diabetic NOD mice. Although this 
was not statistically significant, there was a trend to a delay and reduction in diabetes 
development in the recipients that were transferred with APCs from mice prenatally 
exposed to neomycin, compared to that from the control mice (Fig.7C). Together with 
the results shown in Fig. 6, we suggest that diabetes protection induced by prenatal 
exposure to neomycin could be mediated, in part, by APCs. 
 
3.9 Cytokine profile of T cells in the recipient mice 
In a similar but separate set of adoptive transfer experiments to those shown in 
Fig.7B, some recipient mice were sacrificed 4 weeks after the adoptive transfer of 
purified T cells from diabetic NOD mice. We examined the profile of intracellular 
cytokine expression in the T cells from the spleen, MLN and PLN. Although the recipient 
mice were adoptively transferred with the same diabetogenic T cells, fewer IFN- and 
IL-17 expressing CD4+ T cells were found in the recipient mice that were prenatally 
 18 
exposed to neomycin, compared to vancomycin and control groups (Fig.8). These results 
further support the notion that APCs are the link between the suppressed inflammatory 
phenotype of T cells and diabetes protection in the progeny of neomycin-treated mice. 
 
3.10 Diabetes protection can be vertically transmitted to the second generation 
To investigate whether the protected or accelerated diabetes phenotype, in the mice 
prenatally exposed to neomycin and vancomycin, respectively, can be inherited by the 
next generation, we bred the mice that were prenatally exposed to neomycin or 
vancomycin. As controls, we also bred the progeny of untreated mice. Diabetes 
development was observed in the offspring of this breeding. It is interesting that 
diabetes protection due to prenatal neomycin exposure can be passed on to the second 
generation whereas the phenotype of accelerated diabetes seen in the progeny of 
vancomycin-treated mice was lost in the second generation (Fig.9). This suggests that 




In this study, we investigated the effects of type and timing of antibiotic treatment, 
particularly at the earliest stages of life. We showed that neomycin treatment of 
pregnant NOD mice altered the gut bacterial composition and protected the offspring 
from diabetes and moreover, this protection could be transmitted to the second 
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generation. This protection with neomycin, which was associated with a reduction in 
immunogenic phenotype in the APC of the spleen and gut-draining lymph nodes and 
reduced capacity to stimulate pathogenic autoantigen-specific CD4 and CD8 T cells, is 
most likely mediated by altered gut microbiota. In sharp contrast, prenatal exposure to 
vancomycin, by treatment of the mothers, induced changes in the microbiota that 
accelerated diabetes in the offspring, but this phenotype was not transmitted to the next 
generation. The vancomycin-treated offspring had more activated/memory 
inflammatory T cells in the gut and pancreatic-draining lymph nodes. Our results provide 
evidence that alteration of gut bacteria in the mother has a significant effect on immune 
development and manifestation of autoimmune diabetes in the offspring. 
The use of antibiotics will alter the composition of gut microbiota [32, 33]. This short 
period of continuous prenatal exposure to both neomycin and vancomycin induced 
distinct changes in the gut microbiome in the offspring compared with the progeny from 
the untreated NOD mothers. These differences were maintained far beyond the 
postnatal period, even after the antibiotics had been withdrawn for a very long time. 
Our approach allowed us to assess the effect of setting the bacterial composition early in 
life and how this determined the immune responses later on. However, the individual 
effect of any given antibiotic on the bacterial composition is subject to other 
environmental influences, and the composition of the gut microbiota is not static. In our 
current study, the length of treatment and age at which treatment was given was 
particularly important. With this treatment protocol, we showed that the clearest effect 
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on diabetes development occurred when the treatment was administered in the 
prenatal period. The mice were exposed to the specific bacteria from the mother, 
shaped by the treatment before birth and the bacterial composition in the very early 
stages of their life was critical for diabetes susceptibility. It is known that early life 
influences, starting from the flora set at the time of birth, shape the developing immune 
system both in mice [34, 35] and humans [36, 37]. This indicates that the initial flora, 
ǁhiĐh Ŷot oŶly ͞eduĐate͟ the iŵŵuŶe systeŵ ďut also affeĐt the respoŶse to other 
influences in the environment, are critical. Thus, it is not surprising that some of the 
studies by different investigators, in different environments have shown divergent effects. 
Our studies using vancomycin accord with the investigations where the same antibiotic 
used continuously from birth accelerated diabetes onset, although only in male mice 
[38], or when given through gestation and continued through life [39]. These continuous 
treatments maintained the composition of the microbiota, and thus, prolonged the 
effects, suggesting that the microbiota that is set very early have a substantial effect. 
However, it should be noted that long-term antibiotic treatment raises a concern about 
propagation of resistant bacterial strains in the gut [40]. Even the 3-week treatment of 
the pregnant females, using neomycin or vancomycin, could cause increase of some G- 
or G+ bacteria, respectively, which are possibly neomycin or vancomycin resistant (data 
not shown). These studies contrast with the study by Hansen and colleagues who 
showed when vancomycin was given after birth for 4 weeks or from the age of 8 weeks 
onwards, there was protection from diabetes [41], and indeed this accords with our data 
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that no acceleration of diabetes occurred when vancomycin was given after birth for 3 
weeks (data not shown). Overall, the studies suggest that early timing has a particular 
effect, but if started later, the length of antibiotic usage might make an important 
contribution to the immunological phenotype and development of autoimmunity. 
How does the composition of bacteria alter the development of diabetes? The 
bacteria could have a direct or indirect effect. Here, NOD mice exposed to vancomycin at 
the prenatal stage developed diabetes more rapidly and the mice also had more 
inflammatory T cells. Several factors could contribute to this. Firstly, DC/macrophages 
may mature quicker as a result of increased gut permeability, as we demonstrated with 
vancomycin treatment, and this could lead to increased stimulation with microbial 
antigens. It is known that DC can interact directly with the gut luminal contents and the 
bacteria in the layers of the gut wall via pseudopodia. Secondly, in a separate study, we 
have evidence that some bacteria can stimulate diabetogenic CD8 T cells through the 
mechanism of molecular mimicry (manuscript submitted). These stimulated CD8 T cells 
in the gut could then migrate to islets and accelerate diabetes. 
However, not all the antibiotics promote diabetes development. Neomycin 
treatment encouraged predominance of different bacterial genera and this was 
associated with protection from diabetes. Our approach suggested that prenatal 
neomycin treatment may induce protective APCs. This result is consistent with our 
previous study showing that maternal treatment with Neomycin/Polymyxin 
B/Streptomycin, all targeting Gram-negative bacteria, protected offspring from diabetes 
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by generation of tolerogenic APCs. Importantly, the protection could also be transmitted 
to the next generation. The mice had reduced gut permeability and the APC had a less 
inflammatory phenotype. These changes in the immune cells were not related to a direct 
effect of antibiotic treatment, as firstly, the mice (offspring) did not have direct contact 
with antibiotics; secondly, both purified T cells and APCs treated in culture with 
neomycin or vancomycin in vitro had similar profiles of cytokines, co-stimulation and 
activation markers (data not shown). However, our results showed that the offspring of 
vancomycin-treated breeders developed accelerated diabetes and they also had 
increased gut permeability, whereas the offspring of neomycin-treated breeders were 
protected from diabetes and these mice showed reduced gut permeability.  Thus the 
͞leaky gut͟ is associated with the disease onset but further work would be required to 
demonstrate causation. However, what has been shown here is that the ͞leaky gut͟ was 
unlikely to be a direct consequence of antibiotic exposure as the mice did not have 
direct gut exposure to the antibiotics. Furthermore, the gut permeability test was 
examined in adulthood. It has been reported that antibiotic treatment could affect 
beneficial bacteria that control the growth of fungi in the gut [42]. Toxins produced by 
the fungi could lead to the increased gut permeability [42]. It is not clear whether this is 
the case in the offspring of vancomycin-treated breeders; however, these mice have 
altered gut microbiota even they have not had direct contact with antibiotics. It is also 
not clear that whether indirect antibiotic exposure during fetal development could result 
in epigenetic changes. What is clear, however, is that the composition of gut microbiota 
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in the offspring of antibiotic-treated breeders is very different from the offspring of 
untreated breeders. It is also noteworthy that the altered gut microbiota in the offspring 
are very stable. Thus, the changes in the immune cells are most likely due to the changes 
in gut microbiota, which are known to affect the host immune system, to polarize more 
towards an inflammatory or tolerant phenotype. 
It had been suggested that APC dysfunction leads to diabetes development [43, 44], 
but this had not previously been correlated with gut bacterial composition. Supporting 
our previous finding with the combined treatment using three antibiotics [20], we found 
that prenatal exposure to neomycin alone may induce similar immune tolerance, and 
the disease protection was transferrable to the second generation or other hosts. 
Our study has a number of important implications. Firstly, effects of antibiotics in 
pregnancy could have important implications for determining gut bacteria at the time of 
birth and subsequently influence the immunopathogenesis of autoimmune diabetes. 
Secondly, alteration of gut bacteria could potentially lead to the generation of 
tolerogenic APCs, which might be used as an indicator to monitor immuno-therapy. 
Thirdly, our study reinforces the possibility that using probiotics (a combination of 
beneficial gut microbiota) early in life could have a major immuno-modulatory effect. 
This approach would provide an easy to administer preventative treatment. It will 
require, however, that we more precisely identify a ͞ďeŶefiĐial͟ ĐolleĐtioŶ of ďaĐteria 
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Fig. 1. Diabetes incidence in NOD mice prenatally-treated with Neomycin or Vancomycin. 
NOD: untreated control. Neo: Neomycin-treated. Van: Vancomycin-treated. *: P<0.05, **: 
P<0.01, ****: P<0.0001 (Log-rank (Mantel-Cox) test). 
 
 
Fig. 2. Impact of prenatal antibiotic treatment on 4-week-old NOD mice. (A) Cecum 
weight. (B) Gut permeability assay. (C) Total lymphocytes in MLN and PP. *: P<0.05, **: 
P<0.01, ***: P<0.001, ****: P<0.0001 ;“tudeŶt’s t-test). 
 
Fig. 3. Bacterial changes after antibiotic treatment in NOD mice. (A) Bacterial 
composition at phylum level in mothers after 3 weeks of treatment with antibiotics. (B) 
Actinobacteria and Cyanobacteria percentage in feces from mothers. (C) Bacterial 
composition at genus level in feces from mothers. (D) Actinobacteria and Cyanobacteria 
percentage in feces from offspring at 4 weeks and 15 weeks of age. (E) Gram+ to Gram- 
ratio in feces from offspring. (F) SFB percentage in feces from offspring by qPCR. *: 
P<0.05, **: P<0.01, ****: P<0.0001 ;“tudeŶt’s t-test). 
 
Fig. 4. T cell profiling of SPL, MLN, PLN and PP from NOD prenatally-treated with 
neomycin or vancomycin at 4-5 weeks of age. Lymphocytes were gated on CD4+ or CD8+ 
and the expression of surface or ICC markers was examined. (A) Naïve and Memory CD4 
T cells. (B) IL17-expressing CD4 T cells. (C) IFN-expressing CD8 T cells. (D): 
TNF-expressing CD8 T cells. Representative FACS plots from PLN. ns: not significant, *: 
P<0.05, **: P<0.01, ***: P<0.001 (“tudeŶt’s t-test). 
 
Fig. 5. APC profiling of SPL, MLN after prenatal antibiotic exposure. Cells were gated on 
CD11b+ or CD11c+ cells and CD80 and CD86 expression was examined. (A) CD80 and 
CD86 expressing CD11b+ cells. Representative FACS plots of CD11b+CD86+ cells from 
MLN. (B) CD80 and CD86 expressing CD11c+ cells. (C) Total lymphocytes were isolated 
and stimulated with LPS or CPG and tested for IFN-expressing CD11b+ and CD11c+ cells. 
(D) IFN expressing CD11b+ and CD11c+ cells from prenatally antibiotic-treated NOD. *: 
P<0.05, **: P<0.01, ***: P<0.001 (“tudeŶt’s t-test). 
 
Fig. 6. In vitro function of APC from prenatal antibiotic-treated NOD mice. (A) BDC2.5 
CD4 T cell proliferation following stimulation with mimotope peptide presented by APC 
from the different groups of mice. (B): NY8.3 CD8 T cells proliferation stimulated with 
specific IGRP peptide presented by APC from the different groups of mice. *: P<0.05, **: 
P<0.01, ***: p<0.001 (Two way ANOVA). 
 
Fig. 7. Adoptive transfer assay. (A) Recipients: prenatal antibiotic-treated or untreated 
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NOD mice at 6 weeks of age. Donor cells: total splenocytes from diabetic NOD mice. (B) 
Recipients: prenatal antibiotic-treated or untreated NOD mice at 6 weeks of age. Donor 
cells: purified T cells from diabetic NOD mice. (C) Recipients: irradiated 6-week-old NOD 
mice. Donor cells: purified T cells from diabetic NOD mice with or without total APC from 
prenatally neomycin-treated or untreated NOD mice. *: P<0.05, **: P<0.01 (Log-rank 
(Mantel-Cox) test). 
 
Fig. 8. Th1 and Th17 profiling of T cells from mice adoptively transferred with 
diabetogenic T cells. NOD: NOD mice as recipients; Neo: Prenatal neomycin-treated mice 
as recipients; Van: Prenatal vancomycin-treated mice as recipients. 
IFN-expressing CD4 T cells (left) and IL17-expressing CD4 T cells (right). Representative 
FACS plots: IL17-expressing CD4 T cells from SPL. *: P<0.05, **: P<0.01 (“tudeŶt’s t-test). 
 
Fig. 9. Diabetes incidence in the offspring of prenatal antibiotic-treated NOD mice. NOD: 
untreated NOD control mice; Neo: 2nd generation of prenatally neomycin-treated NOD 
mice; Van: 2nd generation of prenatal vancomycin-treated NOD mice. *: P<0.05 
(Log-rank (Mantel-Cox) test). 
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